Abbott has reported positive data from the Leadless II IDE trial, which assessed its Aveir leadless pacemaker for the treatment of patients with certain types of abnormal heartbeats.
The Aveir system is claimed to be the only leadless pacemaker in the world designed to be retrievable when the system either needs to be replaced or if a patient’s course of therapy requires alteration.
The Leadless II IDE trial is a multicentre, non-randomised, prospective study to assess the device’s efficacy and safety in patients indicated for a ventricular pacing on-demand or VVI(R), which stimulates heartbeats only if the rate goes below the required level.
